<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 2.25pt 0 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>Date of Report (Date of earliest event
reported): January 23, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>NEUROLOGIX, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact Name of Registrant as Specified in
Charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">000-13347</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">06-1582875</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or Other Jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt; text-align: center"><B>of Incorporation</B></P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(Commission File Number)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">One Bridge Plaza, Fort Lee, New Jersey</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">07024</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (201) 592-6451</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><B>Not Applicable </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>During and Kaplitt Letter Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Neurologix, Inc. (the &ldquo;Company&rdquo;)
entered into a letter agreement (the &ldquo;During Letter Agreement&rdquo;), dated January 25, 2012, with Dr. Matthew J. During.
The During Letter Agreement amends, effective as of January 25, 2012, that certain Consulting Agreement, dated as of October 1,
1999, by and between Dr. Matthew J. During and the Company (the &ldquo;During Consulting Agreement&rdquo;). Dr.&nbsp; During is
one of the Company&rsquo;s scientific co-founders and a member of its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Additionally, the Company entered into a letter
agreement (the &ldquo;Kaplitt Letter Agreement&rdquo; and together with the During Letter Agreement, the &ldquo;Letter Agreements&rdquo;),
dated January 26, 2012, with Dr. Michael G. Kaplitt.&nbsp;&nbsp;The Kaplitt Letter Agreement amends, effective as of January 26,
2012, that certain Amended and Restated Consulting Agreement, dated as of April&nbsp;25, 2005, by and between Dr.&nbsp;Michael
G. Kaplitt and Neurologix Research, Inc., the predecessor by merger to the Company (the &ldquo;Kaplitt Consulting Agreement&rdquo;).
Dr.&nbsp;Kaplitt is one of the Company&rsquo;s scientific co-founders and a member of its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Under the terms of the During Letter Agreement
and the Kaplitt Letter Agreement, Drs. During and Kaplitt, respectively, agree to advise the Company in connection with a potential
strategic opportunity and to provide advice and assistance in connection with a Liquidity Event (defined below). Additionally,
under the terms of the Letter Agreements, Drs. During and Kaplitt will no longer be entitled to compensation by the Company in
the form of annual retainers (including any compensation previously owed to Drs. During or Kaplitt under the During Consulting
Agreement or Kaplitt Consulting Agreement, respectively), but will receive as consideration in lieu thereof an amount equal to
3.5% of the aggregate consideration received by the Company or its stockholders in connection with a Liquidity Event. Drs. During
and Kaplitt will not receive any other compensation for their consulting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&ldquo;Liquidity Event&rdquo; means (i) <FONT STYLE="letter-spacing: -0.15pt">any
merger, consolidation, reorganization or other business combination pursuant to which the business of the Company is combined with
that of one or more purchasers or sellers or one or more persons formed by, or affiliated with, a purchaser or seller, (ii) the
acquisition, directly or indirectly, by one or more purchasers of more than 50% of the capital stock of the Company, by way of
negotiated purchase or any other means (but specifically excluding any purchase of capital stock from the Company for the purposes
of capital raising), (iii) the acquisition, directly or indirectly, by one or more purchasers of all or substantially all of the
assets of the Company, or (iv) any licensing, collaboration, partnership, joint venture, strategic alliance or similar transaction,
business association or relationship with one or more strategic parties with respect to the development, commercialization, marketing,
promotion, sale and/or distribution of the Company&rsquo;s gene therapy product for the treatment of Parkinson&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In connection with the Letter Agreements,
Drs. During and Kaplitt each signed a general release of all claims against the Company, including any claims related to compensation
previously owed to Drs. During or Kaplitt under the During Consulting Agreement or Kaplitt Consulting Agreement, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The preceding summary of the Letter Agreements is qualified in its
entirety by reference to the full text of the Letter Agreements, copies of which are attached hereto as Exhibits&nbsp;10.1 and
10.2 and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Hardy Letter Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 23, 2012, the Company entered into a letter agreement
(the &ldquo;Hardy Letter Agreement&rdquo;) with Reginald Hardy, a Director and Vice President of the Company. The Hardy Letter
Agreement amends, effective as of January 23, 2012, that certain letter agreement, dated as of December 15, 2011, by and between
the Company and Reginald Hardy (the &ldquo;Hardy Employment Agreement&rdquo;). Pursuant to the terms of the Hardy Letter Agreement,
Mr. Hardy will receive 3.5% of (i) any up-front payment received by the Company in a Liquidity Event and (ii) any future milestone
payments received by the Company in a Liquidity Event. Mr. Hardy was previously entitled to 4% of such payments under the Hardy
Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The preceding summary of the Hardy Letter Agreement is qualified
in its entirety by reference to the full text of the Hardy Letter Agreement, a copy of which is attached hereto as Exhibit&nbsp;10.3
and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01. Financial Statements and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">(c)</TD>
    <TD>Exhibits</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-left: 0; border-collapse: collapse; margin-right: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-bottom: 6pt">10.1</TD>
    <TD STYLE="width: 92%; padding-bottom: 6pt">Letter agreement, dated January 25, 2012, by and between the Company and Dr. Matthew J. During.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">10.2</TD>
    <TD STYLE="padding-bottom: 6pt">Letter Agreement, dated January 26, 2012, by and between the Company and Dr. Michael G. Kaplitt.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt">10.3</TD>
    <TD STYLE="padding-bottom: 6pt">Letter Agreement, dated January 23, 2012, by and between the Company and Reginald Hardy.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">NEUROLOGIX, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;Date: January 27, 2012</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ Marc L. Panoff&nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-indent: 0; text-align: justify">Name:
Marc L. Panoff&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify">Title:
Chief Financial Officer, Secretary and Treasurer&nbsp;</P>
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v300614_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 19420}]
{"company-data": {"conformed-name": "NEUROLOGIX INC/DE", "cik": "0000356591", "assigned-sic": "2834", "irs-number": "061582875", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-13347", "film-number": "12550736"}, "business-address": {"street1": "ONE BRIDGE PLAZA", "city": "FORT LEE", "state": "NJ", "zip": "07024", "phone": "201-592-6451"}, "mail-address": {"street1": "ONE BRIDGE PLAZA", "city": "FORT LEE", "state": "NJ", "zip": "07024"}, "former-company": [{"former-conformed-name": "CHANGE TECHNOLOGY PARTNERS INC", "date-changed": "20000907"}, {"former-conformed-name": "ARINCO COMPUTER SYSTEMS INC", "date-changed": "19920703"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 23, 2012
NEUROLOGIX, INC.
(Exact Name of Registrant as Specified in
Charter)
Delaware
000-13347
06-1582875
(State or Other Jurisdiction
of Incorporation
(Commission File Number)
(IRS Employer
Identification No.)
One Bridge Plaza, Fort Lee, New Jersey
07024
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code: (201) 592-6451
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
During and Kaplitt Letter Agreements
Neurologix, Inc. (the "Company")
entered into a letter agreement (the "During Letter Agreement"), dated January 25, 2012, with Dr. Matthew J. During.
The During Letter Agreement amends, effective as of January 25, 2012, that certain Consulting Agreement, dated as of October 1,
1999, by and between Dr. Matthew J. During and the Company (the "During Consulting Agreement"). Dr.  During is
one of the Company's scientific co-founders and a member of its Scientific Advisory Board.
Additionally, the Company entered into a letter
agreement (the "Kaplitt Letter Agreement" and together with the During Letter Agreement, the "Letter Agreements"),
dated January 26, 2012, with Dr. Michael G. Kaplitt.  The Kaplitt Letter Agreement amends, effective as of January 26,
2012, that certain Amended and Restated Consulting Agreement, dated as of April 25, 2005, by and between Dr. Michael
G. Kaplitt and Neurologix Research, Inc., the predecessor by merger to the Company (the "Kaplitt Consulting Agreement").
Dr. Kaplitt is one of the Company's scientific co-founders and a member of its Scientific Advisory Board.
Under the terms of the During Letter Agreement
and the Kaplitt Letter Agreement, Drs. During and Kaplitt, respectively, agree to advise the Company in connection with a potential
strategic opportunity and to provide advice and assistance in connection with a Liquidity Event (defined below). Additionally,
under the terms of the Letter Agreements, Drs. During and Kaplitt will no longer be entitled to compensation by the Company in
the form of annual retainers (including any compensation previously owed to Drs. During or Kaplitt under the During Consulting
Agreement or Kaplitt Consulting Agreement, respectively), but will receive as consideration in lieu thereof an amount equal to
3.5% of the aggregate consideration received by the Company or its stockholders in connection with a Liquidity Event. Drs. During
and Kaplitt will not receive any other compensation for their consulting services.
"Liquidity Event" means (i)
any
merger, consolidation, reorganization or other business combination pursuant to which the business of the Company is combined with
that of one or more purchasers or sellers or one or more persons formed by, or affiliated with, a purchaser or seller, (ii) the
acquisition, directly or indirectly, by one or more purchasers of more than 50% of the capital stock of the Company, by way of
negotiated purchase or any other means (but specifically excluding any purchase of capital stock from the Company for the purposes
of capital raising), (iii) the acquisition, directly or indirectly, by one or more purchasers of all or substantially all of the
assets of the Company, or (iv) any licensing, collaboration, partnership, joint venture, strategic alliance or similar transaction,
business association or relationship with one or more strategic parties with respect to the development, commercialization, marketing,
promotion, sale and/or distribution of the Company's gene therapy product for the treatment of Parkinson's disease.
In connection with the Letter Agreements,
Drs. During and Kaplitt each signed a general release of all claims against the Company, including any claims related to compensation
previously owed to Drs. During or Kaplitt under the During Consulting Agreement or Kaplitt Consulting Agreement, respectively.
The preceding summary of the Letter Agreements is qualified in its
entirety by reference to the full text of the Letter Agreements, copies of which are attached hereto as Exhibits 10.1 and
10.2 and are incorporated herein by reference.
Hardy Letter Agreement
On January 23, 2012, the Company entered into a letter agreement
(the "Hardy Letter Agreement") with Reginald Hardy, a Director and Vice President of the Company. The Hardy Letter
Agreement amends, effective as of January 23, 2012, that certain letter agreement, dated as of December 15, 2011, by and between
the Company and Reginald Hardy (the "Hardy Employment Agreement"). Pursuant to the terms of the Hardy Letter Agreement,
Mr. Hardy will receive 3.5% of (i) any up-front payment received by the Company in a Liquidity Event and (ii) any future milestone
payments received by the Company in a Liquidity Event. Mr. Hardy was previously entitled to 4% of such payments under the Hardy
Employment Agreement.
The preceding summary of the Hardy Letter Agreement is qualified
in its entirety by reference to the full text of the Hardy Letter Agreement, a copy of which is attached hereto as Exhibit 10.3
and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c)
Exhibits
10.1
Letter agreement, dated January 25, 2012, by and between the Company and Dr. Matthew J. During.
10.2
Letter Agreement, dated January 26, 2012, by and between the Company and Dr. Michael G. Kaplitt.
10.3
Letter Agreement, dated January 23, 2012, by and between the Company and Reginald Hardy.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEUROLOGIX, INC.
Date: January 27, 2012
By:
/s/ Marc L. Panoff
Name:
Marc L. Panoff
Title:
Chief Financial Officer, Secretary and Treasurer